Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.37 |
| ▸ | CA2 | P00918 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | CA9 | Q16790 | 4/20 | 0.34 |
| ▸ | CA12 | O43570 | 3/20 | 0.34 |
| ▸ | CA7 | P43166 | 3/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | TTR | P02766 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1056663 | 0.86 | CA1 (0.42) | CA1CA2ALDH1A1CA9CA12 | |
| SCHEMBL5702524 | 0.79 | HSD17B10 (0.41) | CA1CA2ALDH1A1CA9CA12 | |
| SCHEMBL27584645 | 0.79 | TRPA1 (0.43) | CA1CA2ALDH1A1CA9CA12 | |
| SCHEMBL29811015 | 0.77 | MEN1 (0.57) | CA1CA2ALDH1A1CA9CA12 | |
| SCHEMBL548021 | 0.77 | MEN1 (0.57) | CA1CA2ALDH1A1CA9CA12 | |
| SCHEMBL10334392 | 0.76 | TP53 (0.52) | CA1CA2ALDH1A1CA9CA12 | |
| SCHEMBL31371002 | 0.76 | HCAR1 (0.32) | CA1CA2CA9 | |
| SCHEMBL28870480 | 0.76 | MEN1 (0.58) | CA1CA2ALDH1A1CA9MEN1 | |
| SCHEMBL4613843 | 0.74 | CA1 (0.52) | CA1CA2ALDH1A1CA9CA12 | |
| SCHEMBL28814954 | 0.71 | HSD11B1 (0.51) | CA1CA2ALDH1A1CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084118-A1 | NOVEL DEALKOXYPHENYLATION REACTION | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-03-13 | — | — | US | claimed |
| US-20240279364-A1 | GLYCAN, AND METHOD FOR PRODUCING MEDICINE CONTAINING GLYCAN | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-08-22 | — | — | US | claimed |
| EP-4306546-A1 | GLYCAN, AND METHOD FOR PRODUCING MEDICINE CONTAINING GLYCAN | Daiichi Sankyo Company, Limited (JP) | 2024-01-17 | — | — | EP | claimed |
| EP-4306501-A1 | NOVEL DEALKOXYPHENYLATION REACTION | Daiichi Sankyo Company, Limited (JP) | 2024-01-17 | — | — | EP | claimed |
| WO-2022191312-A1 | NOVEL DEALKOXYPHENYLATION REACTION | 第一三共株式会社 | 2022-09-15 | — | — | WO | claimed |
| WO-2022191313-A1 | GLYCAN, AND METHOD FOR PRODUCING MEDICINE CONTAINING GLYCAN | 第一三共株式会社 | 2022-09-15 | — | — | WO | claimed |
| US-20190271658-A1 | OXIDIZING AGENT FOR ELECTRON MEDIATOR | PHC HOLDINGS CORPORATION (JP) | 2019-09-05 | — | — | US | claimed |
| EP-3531120-A1 | OXIDIZING AGENT FOR ELECTRON MEDIATOR | PHC Holdings Corporation (JP) | 2019-08-28 | — | — | EP | claimed |
| US-20250346622-A1 | NOVEL OLIGOSACCHARIDE, MANUFACTURING INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE, AND METHOD FOR MANUFACTURING THESE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-11-13 | — | — | US | disclosed |
| EP-4585601-A1 | NOVEL OLIGOSACCHARIDE, PRODUCTION INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE, PRODUCTION METHOD FOR NOVEL OLIGOSACCHARIDE, AND PRODUCTION METHOD FOR PRODUCTION INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE | Daiichi Sankyo Company, Limited (JP) | 2025-07-16 | — | — | EP | disclosed |
| US-20250084118-A1 | NOVEL DEALKOXYPHENYLATION REACTION | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-03-13 | — | — | US | disclosed |
| EP-4424717-A1 | NOVEL OLIGOSACCHARIDE, MANUFACTURING INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE, AND METHOD FOR MANUFACTURING THESE | Daiichi Sankyo Company, Limited (JP) | 2024-09-04 | — | — | EP | disclosed |
| US-20240279364-A1 | GLYCAN, AND METHOD FOR PRODUCING MEDICINE CONTAINING GLYCAN | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-08-22 | — | — | US | disclosed |
| WO-2024053574-A1 | NOVEL OLIGOSACCHARIDE, PRODUCTION INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE, PRODUCTION METHOD FOR NOVEL OLIGOSACCHARIDE, AND PRODUCTION METHOD FOR PRODUCTION INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE | 第一三共株式会社 | 2024-03-14 | — | — | WO | disclosed |
| US-7423146-B2 | Process for the manufacturing of pharmaceutically active 3,1-benzoxazine-2-ones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-09-09 | — | — | US | disclosed |
| EP-1948625-A1 | PROCESS FOR THE PREPARATION OF BETAMIMETIC BENZOXAZINONE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-30 | — | — | EP | disclosed |
| EP-1934214-A1 | OXADIAZOLYL PYRAZOLO-PYRIMIDINES AS MGLUR2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007054484-A1 | PROCESS FOR THE PREPARATION OF BETAMIMETIC BENZOXAZINONE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-18 | — | — | WO | disclosed |
| US-20070112191-A1 | Process for the manufacturing of pharmaceutically active compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-17 | — | — | US | disclosed |
| WO-2007039439-A1 | OXADIAZOLYL PYRAZOLO-PYRIMIDINES AS MGLUR2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279364-A1 | GLYCAN, AND METHOD FOR PRODUCING MEDICINE CONTAINING GLYCAN | FUT6, ST6GAL1, NEU2 | CA1 1400/4885CA2 1784/4885ALDH1A1 748/4885 |
| US-20070112191-A1 | Process for the manufacturing of pharmaceutically active compounds | FIP1L1, TET2, F3 | CA1 2732/4885CA2 2298/4885ALDH1A1 543/4885 |
| US-20250084118-A1 | NOVEL DEALKOXYPHENYLATION REACTION | FOS, ADH1C, ADH5 | CA1 3428/4885CA2 3992/4885ALDH1A1 990/4885 |
| US-20190271658-A1 | OXIDIZING AGENT FOR ELECTRON MEDIATOR | NOX4, LPO, SQOR | CA1 617/4885CA2 871/4885ALDH1A1 274/4885 |
| US-20250346622-A1 | NOVEL OLIGOSACCHARIDE, MANUFACTURING INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE, AND METHOD FOR MANUFACTURING THESE | FUT6, FUT5, ST3GAL3 | CA1 1484/4885CA2 3245/4885ALDH1A1 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.